Samuel Bjork, a Partner at Digitalis Ventures, primarily invests in biotech, therapeutics. See sector focus and contact routes.
Samuel Bjork, a Partner at Digitalis Ventures, primarily invests in biotech, therapeutics, and digital health at the Seed and Series A stages, with check sizes typically ranging from $100K to $5.0M (sweet spot ~$1.5M). His notable portfolio includes board directorships at Judo Bio, T-Therapeutics, EpiBiologics, and Bonum Therapeutics, alongside investments in Good Therapeutics and Elemental Machines. Bjork’s distinctive thesis aligns with Digitalis’s focus on “engineering health,” combining breakthrough science with technology-enabled solutions to address unmet needs in both human and animal health.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in New York when building a target list.
Investors like Samuel Bjork · Full investor directory · Investor access · Company funding database